Tag: Sanofi-aventis
Sanofi-aventis announces results of research in the use of Lantus®(...
1. Two new meta-analyses confirm once-daily Lantus® efficacy and reduced risk of hypoglycaemia compared to NPH Insulin
2. With lower dose, Lantus® achieves similar and...
Sanofi-aventis welcomes the European Medicines Agency’s statement on Lantus® safety
Based on existing evidence CHMP (the EMEA’s Committee for Medicinal Products for Human Use) concludes that no changes to the prescribing advice are necessary
Sanofi-aventis...
Sanofi-aventis stands behind the safety of Lantus
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results...